View ValuationGenic 将来の成長Future 基準チェック /06現在、 Genicの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長30.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • May 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩23,250, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 421% over the past three years.Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩28,750, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 523% over the past three years.Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩2,414 (vs ₩1,036 in FY 2024)Full year 2025 results: EPS: ₩2,414 (up from ₩1,036 in FY 2024). Revenue: ₩78.2b (up 57% from FY 2024). Net income: ₩18.9b (up 150% from FY 2024). Profit margin: 24% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 10Genic Co., Ltd., Annual General Meeting, Mar 24, 2026Genic Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₩16,570, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 227% over the past three years.分析記事 • Feb 06Genic Co., Ltd. (KOSDAQ:123330) Looks Just Right With A 42% Price JumpGenic Co., Ltd. ( KOSDAQ:123330 ) shareholders would be excited to see that the share price has had a great month...Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 350% over the past three years.New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (25% accrual ratio).Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩18,980, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 280% over the past three years.分析記事 • Dec 04These 4 Measures Indicate That Genic (KOSDAQ:123330) Is Using Debt SafelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩17,900, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 282% over the past three years.New Risk • Nov 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.1b (US$92.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (₩135.1b market cap, or US$92.2m).分析記事 • Nov 03Under The Bonnet, Genic's (KOSDAQ:123330) Returns Look ImpressiveIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,000, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 469% over the past three years.Valuation Update With 7 Day Price Move • Oct 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 440% over the past three years.Buy Or Sell Opportunity • Aug 12Now 25% undervaluedOver the last 90 days, the stock has risen 20% to ₩31,250. The fair value is estimated to be ₩41,431, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.分析記事 • Jul 15Does Genic (KOSDAQ:123330) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jun 16A Look At The Fair Value Of Genic Co., Ltd. (KOSDAQ:123330)Key Insights Genic's estimated fair value is ₩42,934 based on 2 Stage Free Cash Flow to Equity Genic's ₩41,750 share...Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩41,600, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 857% over the past three years.分析記事 • May 26After Leaping 37% Genic Co., Ltd. (KOSDAQ:123330) Shares Are Not Flying Under The RadarGenic Co., Ltd. ( KOSDAQ:123330 ) shares have had a really impressive month, gaining 37% after a shaky period...Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩31,750, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Personal Products industry in South Korea. Total returns to shareholders of 477% over the past three years.分析記事 • May 23Genic (KOSDAQ:123330) Is Very Good At Capital AllocationIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...分析記事 • Apr 09Risks Still Elevated At These Prices As Genic Co., Ltd. (KOSDAQ:123330) Shares Dive 25%To the annoyance of some shareholders, Genic Co., Ltd. ( KOSDAQ:123330 ) shares are down a considerable 25% in the last...Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩17,800, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 199% over the past three years.New Risk • Apr 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩147.1b market cap, or US$99.9m).分析記事 • Mar 25Genic's (KOSDAQ:123330) Earnings Aren't As Good As They AppearEven though Genic Co., Ltd. ( KOSDAQ:123330 ) posted strong earnings recently, the stock hasn't reacted in a large way...Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩1,036 (vs ₩643 loss in FY 2023)Full year 2024 results: EPS: ₩1,036 (up from ₩643 loss in FY 2023). Revenue: ₩49.9b (up 78% from FY 2023). Net income: ₩7.56b (up ₩12.0b from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year whereas the company’s share price has increased by 60% per year.お知らせ • Mar 12Genic Co., Ltd., Annual General Meeting, Mar 26, 2025Genic Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South Korea分析記事 • Jan 23Genic (KOSDAQ:123330) Is Experiencing Growth In Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...分析記事 • Dec 26Is Genic (KOSDAQ:123330) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Dec 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$93.5m).New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩2.1b). Less than 3 years of financial data is available. Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$94.3m).New Risk • Dec 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩123.7b market cap, or US$88.1m).分析記事 • Nov 29Genic Co., Ltd.'s (KOSDAQ:123330) Popularity With Investors Under Threat As Stock Sinks 30%The Genic Co., Ltd. ( KOSDAQ:123330 ) share price has softened a substantial 30% over the previous 30 days, handing...New Risk • Nov 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩133.3b (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩133.3b market cap, or US$94.9m).分析記事 • Oct 10There's Reason For Concern Over Genic Co., Ltd.'s (KOSDAQ:123330) Massive 34% Price JumpDespite an already strong run, Genic Co., Ltd. ( KOSDAQ:123330 ) shares have been powering on, with a gain of 34% in...New Risk • Aug 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩42.2b market cap, or US$31.7m).New Risk • Jul 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩26.5b market cap, or US$19.2m).分析記事 • Jul 27Genic Co., Ltd.'s (KOSDAQ:123330) Share Price Not Quite Adding UpThere wouldn't be many who think Genic Co., Ltd.'s ( KOSDAQ:123330 ) price-to-sales (or "P/S") ratio of 0.8x is worth a...分析記事 • Mar 12Genic Co., Ltd.'s (KOSDAQ:123330) Shareholders Might Be Looking For ExitWith a median price-to-sales (or "P/S") ratio of close to 1x in the Personal Products industry in Korea, you could be...New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩2.3b free cash flow). Minor Risk Market cap is less than US$100m (₩28.3b market cap, or US$21.4m).Buying Opportunity • Dec 23Now 25% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₩5,922, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%.Buying Opportunity • Dec 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.0%. The fair value is estimated to be ₩6,492, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • May 18First quarter 2022 earnings released: ₩342 loss per share (vs ₩46.00 profit in 1Q 2021)First quarter 2022 results: ₩342 loss per share (down from ₩46.00 profit in 1Q 2021). Revenue: ₩7.81b (down 25% from 1Q 2021). Net loss: ₩2.35b (down ₩2.66b from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Mar 19Genic (KOSDAQ:123330) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Mar 02New 90-day high: ₩5,660The company is up 53% from its price of ₩3,705 on 02 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 10.0% over the same period.Is New 90 Day High Low • Jan 27New 90-day high: ₩4,700The company is up 28% from its price of ₩3,685 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 18% over the same period.Is New 90 Day High Low • Jan 07New 90-day high: ₩3,995The company is up 2.0% from its price of ₩3,910 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period.分析記事 • Dec 03We Think Genic (KOSDAQ:123330) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Sep 23New 90-day low: ₩3,720The company is down 6.0% from its price of ₩3,975 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Genic は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A123330 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202578,19818,88717,96720,651N/A9/30/202585,47218,30412,12114,743N/A6/30/202577,04814,9186,4968,760N/A3/31/202561,37311,7073,3895,119N/A12/31/202449,9087,563-1,379272N/A9/30/202436,668-144-2,203-1,448N/A6/30/202428,940-2,369-1,651-1,443N/A3/31/202428,133-4,229-1,503-1,030N/A12/31/202328,070-4,411-1,110-268N/A9/30/202328,690-4,695-1,689-290N/A6/30/202329,902-2,556-2,292-577N/A3/31/202329,944-1,805-1,170642N/A12/31/202231,449-3,340-1,237186N/A9/30/202233,167-3,7211821,113N/A6/30/202233,525-6,2491,0601,982N/A3/31/202235,849-6,860-270289N/A12/31/202138,408-4,1991,9192,570N/A9/30/202139,846-1,764-2585N/A6/30/202139,067-1,9472,2462,560N/A3/31/202140,319-1181,7882,624N/A12/31/202042,13231-563213N/A9/30/202042,074-1,465-1,047-56N/A6/30/202045,428398-1,593-451N/A3/31/202044,5765294251,164N/A12/31/201943,151-7125011,377N/A9/30/201949,666-2,911N/A2,878N/A6/30/201954,155-8,526N/A-5,363N/A3/31/201960,514-15,562N/A-11,146N/A12/31/201869,027-15,323N/A-8,903N/A9/30/201868,872-14,092N/A-9,411N/A6/30/201868,200-11,975N/A-5,808N/A3/31/201865,889-6,965N/A-691N/A12/31/201764,690-7,467N/A-4,087N/A9/30/201764,376-6,277N/A-2,998N/A6/30/201768,865-2,864N/A-683N/A3/31/201787,880-686N/A713N/A12/31/201689,6681,225N/A1,925N/A9/30/201694,2293,654N/A4,267N/A6/30/201694,2803,263N/A3,890N/A3/31/201675,3732,700N/A2,243N/A12/31/201573,7062,925N/A3,764N/A9/30/201571,1724,476N/A4,901N/A6/30/201567,4794,265N/A5,735N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A123330の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A123330の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A123330の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A123330の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A123330の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A123330の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 06:49終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genic Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Eun Jung ParkDaishin Securities Co. Ltd.Na Young ParkDaiwa Securities Co. Ltd.Choi Soon-HoEugene Investment & Securities Co Ltd.3 その他のアナリストを表示
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩23,250, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 421% over the past three years.
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩28,750, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 523% over the past three years.
Reported Earnings • Mar 20Full year 2025 earnings released: EPS: ₩2,414 (vs ₩1,036 in FY 2024)Full year 2025 results: EPS: ₩2,414 (up from ₩1,036 in FY 2024). Revenue: ₩78.2b (up 57% from FY 2024). Net income: ₩18.9b (up 150% from FY 2024). Profit margin: 24% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 10Genic Co., Ltd., Annual General Meeting, Mar 24, 2026Genic Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₩16,570, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 227% over the past three years.
分析記事 • Feb 06Genic Co., Ltd. (KOSDAQ:123330) Looks Just Right With A 42% Price JumpGenic Co., Ltd. ( KOSDAQ:123330 ) shareholders would be excited to see that the share price has had a great month...
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improves as stock rises 43%After last week's 43% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 350% over the past three years.
New Risk • Feb 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (25% accrual ratio).
Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩18,980, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 280% over the past three years.
分析記事 • Dec 04These 4 Measures Indicate That Genic (KOSDAQ:123330) Is Using Debt SafelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₩17,900, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 282% over the past three years.
New Risk • Nov 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩135.1b (US$92.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (₩135.1b market cap, or US$92.2m).
分析記事 • Nov 03Under The Bonnet, Genic's (KOSDAQ:123330) Returns Look ImpressiveIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩23,000, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 469% over the past three years.
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 440% over the past three years.
Buy Or Sell Opportunity • Aug 12Now 25% undervaluedOver the last 90 days, the stock has risen 20% to ₩31,250. The fair value is estimated to be ₩41,431, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable.
分析記事 • Jul 15Does Genic (KOSDAQ:123330) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jun 16A Look At The Fair Value Of Genic Co., Ltd. (KOSDAQ:123330)Key Insights Genic's estimated fair value is ₩42,934 based on 2 Stage Free Cash Flow to Equity Genic's ₩41,750 share...
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩41,600, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 857% over the past three years.
分析記事 • May 26After Leaping 37% Genic Co., Ltd. (KOSDAQ:123330) Shares Are Not Flying Under The RadarGenic Co., Ltd. ( KOSDAQ:123330 ) shares have had a really impressive month, gaining 37% after a shaky period...
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₩31,750, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Personal Products industry in South Korea. Total returns to shareholders of 477% over the past three years.
分析記事 • May 23Genic (KOSDAQ:123330) Is Very Good At Capital AllocationIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
分析記事 • Apr 09Risks Still Elevated At These Prices As Genic Co., Ltd. (KOSDAQ:123330) Shares Dive 25%To the annoyance of some shareholders, Genic Co., Ltd. ( KOSDAQ:123330 ) shares are down a considerable 25% in the last...
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩17,800, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 199% over the past three years.
New Risk • Apr 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩147.1b market cap, or US$99.9m).
分析記事 • Mar 25Genic's (KOSDAQ:123330) Earnings Aren't As Good As They AppearEven though Genic Co., Ltd. ( KOSDAQ:123330 ) posted strong earnings recently, the stock hasn't reacted in a large way...
Reported Earnings • Mar 22Full year 2024 earnings released: EPS: ₩1,036 (vs ₩643 loss in FY 2023)Full year 2024 results: EPS: ₩1,036 (up from ₩643 loss in FY 2023). Revenue: ₩49.9b (up 78% from FY 2023). Net income: ₩7.56b (up ₩12.0b from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year whereas the company’s share price has increased by 60% per year.
お知らせ • Mar 12Genic Co., Ltd., Annual General Meeting, Mar 26, 2025Genic Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South Korea
分析記事 • Jan 23Genic (KOSDAQ:123330) Is Experiencing Growth In Returns On CapitalTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
分析記事 • Dec 26Is Genic (KOSDAQ:123330) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Dec 09New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$93.5m).
New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩2.1b). Less than 3 years of financial data is available. Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$94.3m).
New Risk • Dec 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩123.7b market cap, or US$88.1m).
分析記事 • Nov 29Genic Co., Ltd.'s (KOSDAQ:123330) Popularity With Investors Under Threat As Stock Sinks 30%The Genic Co., Ltd. ( KOSDAQ:123330 ) share price has softened a substantial 30% over the previous 30 days, handing...
New Risk • Nov 14New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩133.3b (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩133.3b market cap, or US$94.9m).
分析記事 • Oct 10There's Reason For Concern Over Genic Co., Ltd.'s (KOSDAQ:123330) Massive 34% Price JumpDespite an already strong run, Genic Co., Ltd. ( KOSDAQ:123330 ) shares have been powering on, with a gain of 34% in...
New Risk • Aug 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩42.2b market cap, or US$31.7m).
New Risk • Jul 29New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩26.5b market cap, or US$19.2m).
分析記事 • Jul 27Genic Co., Ltd.'s (KOSDAQ:123330) Share Price Not Quite Adding UpThere wouldn't be many who think Genic Co., Ltd.'s ( KOSDAQ:123330 ) price-to-sales (or "P/S") ratio of 0.8x is worth a...
分析記事 • Mar 12Genic Co., Ltd.'s (KOSDAQ:123330) Shareholders Might Be Looking For ExitWith a median price-to-sales (or "P/S") ratio of close to 1x in the Personal Products industry in Korea, you could be...
New Risk • Sep 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩2.3b free cash flow). Minor Risk Market cap is less than US$100m (₩28.3b market cap, or US$21.4m).
Buying Opportunity • Dec 23Now 25% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₩5,922, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%.
Buying Opportunity • Dec 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 3.0%. The fair value is estimated to be ₩6,492, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • May 18First quarter 2022 earnings released: ₩342 loss per share (vs ₩46.00 profit in 1Q 2021)First quarter 2022 results: ₩342 loss per share (down from ₩46.00 profit in 1Q 2021). Revenue: ₩7.81b (down 25% from 1Q 2021). Net loss: ₩2.35b (down ₩2.66b from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Mar 19Genic (KOSDAQ:123330) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Mar 02New 90-day high: ₩5,660The company is up 53% from its price of ₩3,705 on 02 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Jan 27New 90-day high: ₩4,700The company is up 28% from its price of ₩3,685 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 18% over the same period.
Is New 90 Day High Low • Jan 07New 90-day high: ₩3,995The company is up 2.0% from its price of ₩3,910 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period.
分析記事 • Dec 03We Think Genic (KOSDAQ:123330) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Sep 23New 90-day low: ₩3,720The company is down 6.0% from its price of ₩3,975 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.